Eledon Pharmaceuticals, Inc. ELDN 深 沪
交易中 10-12 09:53:11 美东时间
2.495
+0.015
+0.60%
华盛通- 最 高2.58
- 今 开2.50
- 成交量 2.02万股
- 最 低 2.469
- 昨 收 2.48
- 总市值 2.03亿
- 52周最高 4.60
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 1.35
- 委 比 -80.00%
- 总股本 8126.12万
- 历史最高 154.98
- 量 比 1.49
- 振 幅 4.48%
- 历史最低 1.07
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals will present patient-reported outcomes from the Phase 2 BESTOW trial of tegoprubart at the American Society of Nephrology Kidney Week 2026 meeting in Denver. The oral presentation, led by Andrew B. Adams, M.D., Ph.D., will discuss tegoprubart's potential in preventing rejection in kidney transplantation. Tegoprubart is an anti-CD40L antibody targeting immune modulation. The session will take place on October 23, 2026, from ...
10-05 20:05
Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six m...
09-22 19:11
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six m...
09-22 19:10
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Eledon Pharmaceuticals announced updated long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplantation. Results showed that tegoprubart-treated patients maintained statistically significantly higher kidney function (mean eGFR) compared to tacrolimus, with a 13 mL/min/1.73 m² advantage at 24 months (71 vs. 58 mL/min/1.73 m²). No biopsy-proven acute rejections occurred beyond six months post-transplant in the teg...
09-22 11:00
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Eledon Pharmaceuticals announced progress in its tegoprubart development programs for islet cell and kidney transplantation. Key updates include IND submission for a registrational study in type 1 diabetes patients undergoing islet cell transplantation, enrollment of first patients in an investigator-initiated study for islet transplant recipients with renal dysfunction, and compassionate use dosing of tegoprubart for conversion from tacrolimus i...
09-03 11:00
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from the same period last year.
08-14 04:30
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Zurich-based NewcelX Ltd. announced a private placement of 347,134 common shares at a 20% premium to its July 30 closing price, with warrants exercisable at 132% of that price. The offering, including participation from existing shareholders, is expected to close on Aug. 14. Proceeds will support the advancement of NCEL-101, the company's lead type 1 diabetes program, following a successful FDA Pre-IND meeting. CEO Ronen Twito highlighted investo...
07-31 13:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-21 19:53
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significa...
07-01 21:33
